繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Emergent BioSolutions获得6000万美元合同

2026-03-26 04:21

  • Emergent BioSolutions (EBS)  announced on Wednesday it has secured a contract award valued at approximately $54M to deliver CNJ-016® to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. 
  • In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6M. This represents product orders for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) within Emergent’s medical countermeasures portfolio and will support the partner’s smallpox biodefense strategy.
  • The announcement follows Emergent’s recent execution of multi-year agreements with the Government of Canada valued at up to C$140M to support the country’s biologic threat preparedness and response infrastructure, of which more than C$35M in orders will be received in 2026.
  • Source: Press Release

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。